Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy

Autores
Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Fil: Hindie, Elif. Universite de Bordeaux; Francia
Fil: Zanotti Fregonara, Paolo. Universite de Bordeaux; Francia
Fil: Quinto, Michele Arcangelo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universite de Bordeaux; Francia
Fil: Morgat, Clément. Universite de Bordeaux; Francia
Fil: Champion, Christophe. Universite de Bordeaux; Francia
Materia
111in
161tb
177lu
90y
Radiopharmaceutical Therapy
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/52884

id CONICETDig_4de6be485d850aca5b3c3f0ea39b3f2f
oai_identifier_str oai:ri.conicet.gov.ar:11336/52884
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapyHindie, ElifZanotti Fregonara, PaoloQuinto, Michele ArcangeloMorgat, ClémentChampion, Christophe111in161tb177lu90yRadiopharmaceutical Therapyhttps://purl.org/becyt/ford/1.3https://purl.org/becyt/ford/1Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.Fil: Hindie, Elif. Universite de Bordeaux; FranciaFil: Zanotti Fregonara, Paolo. Universite de Bordeaux; FranciaFil: Quinto, Michele Arcangelo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universite de Bordeaux; FranciaFil: Morgat, Clément. Universite de Bordeaux; FranciaFil: Champion, Christophe. Universite de Bordeaux; FranciaSociety of Nuclear Medicine and Molecular Imaging2016-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/52884Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe; Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy; Society of Nuclear Medicine and Molecular Imaging; Journal of Nuclear Medicine; 57; 5; 5-2016; 759-7640161-5505CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://jnm.snmjournals.org/content/57/5/759info:eu-repo/semantics/altIdentifier/doi/10.2967/jnumed.115.170423info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:36:19Zoai:ri.conicet.gov.ar:11336/52884instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:36:19.655CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
title Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
spellingShingle Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
Hindie, Elif
111in
161tb
177lu
90y
Radiopharmaceutical Therapy
title_short Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
title_full Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
title_fullStr Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
title_full_unstemmed Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
title_sort Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy
dc.creator.none.fl_str_mv Hindie, Elif
Zanotti Fregonara, Paolo
Quinto, Michele Arcangelo
Morgat, Clément
Champion, Christophe
author Hindie, Elif
author_facet Hindie, Elif
Zanotti Fregonara, Paolo
Quinto, Michele Arcangelo
Morgat, Clément
Champion, Christophe
author_role author
author2 Zanotti Fregonara, Paolo
Quinto, Michele Arcangelo
Morgat, Clément
Champion, Christophe
author2_role author
author
author
author
dc.subject.none.fl_str_mv 111in
161tb
177lu
90y
Radiopharmaceutical Therapy
topic 111in
161tb
177lu
90y
Radiopharmaceutical Therapy
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.3
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Fil: Hindie, Elif. Universite de Bordeaux; Francia
Fil: Zanotti Fregonara, Paolo. Universite de Bordeaux; Francia
Fil: Quinto, Michele Arcangelo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universite de Bordeaux; Francia
Fil: Morgat, Clément. Universite de Bordeaux; Francia
Fil: Champion, Christophe. Universite de Bordeaux; Francia
description Radiopharmaceutical therapy, traditionally limited to refractory metastatic cancer, is being increasingly used at earlier stages, such as for treating minimal residual disease. The aim of this study was to compare the effectiveness of90Y,177Lu,111In, and161Tb at irradiating micrometastases.90Y and177Lu are widely used β--emitting radionuclides.161Tb is a medium-energy β-radionuclide that is similar to177Lu but emits a higher percentage of conversion and Auger electrons.111In emits -photons and conversion and Auger electrons. Methods: We used the Monte Carlo code CELLDOSE to assess electron doses from a uniform distribution of90Y,177Lu,111In, or161Tb in spheres with diameters ranging from 10 mm to 10 m. Because these isotopes differ in electron energy per decay, the doses were compared assuming that 1 MeV was released per m3, which would result in 160 Gy if totally absorbed. Results: In a 10-mm sphere, the doses delivered by90Y,177Lu,111In, and161Tb were 96.5, 152, 153, and 152 Gy, respectively. The doses decreased along with the decrease in sphere size, and more abruptly so for90Y. In a 100- m metastasis, the dose delivered by90Y was only 1.36 Gy, compared with 24.5 Gy for177Lu, 38.9 Gy for111In, and 44.5 Gy for161Tb. In cell-sized spheres, the dose delivered by111In and161Tb was higher than that of177Lu. For instance, in a 10- m cell,177Lu delivered 3.92 Gy, compared with 22.8 Gy for111In and 14.1 Gy for161Tb. Conclusion:177Lu,111In, and161Tb might be more appropriate than90Y for treating minimal residual disease.161Tb is a promising radionuclide because it combines the advantages of a medium-energy β-emission with those of Auger electrons and emits fewer photons than111In. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
publishDate 2016
dc.date.none.fl_str_mv 2016-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/52884
Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe; Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy; Society of Nuclear Medicine and Molecular Imaging; Journal of Nuclear Medicine; 57; 5; 5-2016; 759-764
0161-5505
CONICET Digital
CONICET
url http://hdl.handle.net/11336/52884
identifier_str_mv Hindie, Elif; Zanotti Fregonara, Paolo; Quinto, Michele Arcangelo; Morgat, Clément; Champion, Christophe; Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: Implications for radiopharmaceutical therapy; Society of Nuclear Medicine and Molecular Imaging; Journal of Nuclear Medicine; 57; 5; 5-2016; 759-764
0161-5505
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://jnm.snmjournals.org/content/57/5/759
info:eu-repo/semantics/altIdentifier/doi/10.2967/jnumed.115.170423
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Society of Nuclear Medicine and Molecular Imaging
publisher.none.fl_str_mv Society of Nuclear Medicine and Molecular Imaging
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614383362113536
score 13.070432